Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Signe Risum; Ulrich Knigge; Seppo W Langer

doi:10.1002/ccr3.1262

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Signe Risum, Ulrich Knigge, Seppo W Langer

Institut for Klinisk Medicin

37 Downloads (Pure)

Abstract

Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

Originalsprog	Engelsk
Tidsskrift	Clinical Case Reports
Vol/bind	5
Udgave nummer	12
Sider (fra-til)	2085-2087
Antal sider	3
ISSN	2050-0904
DOI	https://doi.org/10.1002/ccr3.1262
Status	Udgivet - dec. 2017

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1002/ccr3.1262Licens: CC BY

Hitherto unseen survival in an ALK-positive-patient withadvanced stage adult ganglioneuroblastoma treated withpersonalized medicineForlagets udgivne version, 65,7 KBLicens: CC BY

Citationsformater

@article{8bf08b9122b44e1794f7908f864878eb,

title = "Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine",

abstract = "Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.",

author = "Signe Risum and Ulrich Knigge and Langer, {Seppo W}",

year = "2017",

month = dec,

doi = "10.1002/ccr3.1262",

language = "English",

volume = "5",

pages = "2085--2087",

journal = "Clinical Case Reports",

issn = "2050-0904",

publisher = "JohnWiley & Sons Ltd",

number = "12",

}

TY - JOUR

T1 - Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

AU - Risum, Signe

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2017/12

Y1 - 2017/12

N2 - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

AB - Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports exist of patients surviving up to 5 years (1, 2). We report the clinical and therapeutic course of a patient with stage 4 GNB surviving beyond expectations due to a multimodal treatment approach incorporating new technologies in cancer diagnostic and treatment.

U2 - 10.1002/ccr3.1262

DO - 10.1002/ccr3.1262

M3 - Journal article

C2 - 29225862

SN - 2050-0904

VL - 5

SP - 2085

EP - 2087

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 12

ER -

Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater